Partnering is an essential part of our strategy at Midatech. Midatech’s focus in the first instance is to create and develop valuable assets in house – ie our programmes and our technologies. As these assets progress through various inflexion points towards the clinic, marketing approval and beyond, we have the options of either keeping the assets in house, or actively out-licensing our programmes and/or technologies and sharing the risks and rewards of late stage development with appropriate partners, as well as enter into broader research and development collaborations.
Our programmes and technology platforms have significant clinical and commercial potential. Over the past 5 years we have developed our three proprietary technologies and achieved the major milestones in 2018 of getting each technology to the point where they can now all be used in man. We have commenced first in human clinical trial programmes with each of the technologies, focused on oncology, and established a full GMP manufacturing facility for all our programmes and technologies.
Midatech’s strategy is to focus solely on oncology and immunotherapy, however the platform technologies can be purposed for any indications beyond oncology in which potential partners may be interested.
Partnering opportunities with our programmes and technologies are described below. Contact us for more information.